Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al
This article examines the scientific rationale, current evidence, and important safety considerations surrounding GLP-1 receptor agonists and Parkinson's disease
Replicating that two-signal architecture with exogenous peptides is the mechanistic basis for stacking a GHRH analogue with a GHRP [5]
Under normal conditions (i.e., in the absence of insulin resistance, type 2 diabetes, or obesity), L cells have special protein and fatty acid receptors that help raise intracellular calcium levels, which in turn promote the release of GLP-1s
By influencing telomere biology, it is explored in research focused on cellular aging and genomic stability